Project Grant R37CA304010
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding to the Beckman Research Institute of the City of Hope to conduct research on tumor-selective radiosensitization by targeting hypoxia in rectal cancer. The $662,096 award, active from February 1, 2025 to January 31, 2030, aims to characterize the biology driving the response of locally advanced rectal cancer to standard-of-care treatment and determine if an FDA-approved...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $237,724 to Weill Medical College of Cornell University to conduct research on the role of the p53 gene in determining the ability of radiation therapy to induce an effective anti-tumor immune response. The goal is to identify key determinants that allow radiation therapy to convert a tumor into an "in situ immunization hub" and enhance responses to immune checkpoint...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $585,976 to Providence Health & Services - Oregon to conduct research on enhancing the efficacy of radiation therapy through spatially restricted anti-TGFβ treatment in the tumor microenvironment. The key objectives are to determine the role of self-renewing stem-like CD8+ T cells in local and distant radiation response, and to test radiation therapy combined with...
- This $2,105,127 federal Project Grant was awarded by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395). The grant's objective is to determine the genotypic, phenotypic, and evolutionary trajectories of treatment resistance to radiotherapy. The research team from Northwestern University will: (1) analyze matched pre- and post-radiotherapy genomes from patient tissue and patient-derived xenograft models to elucidate mechanisms of de novo and/or acquired...